ALHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alignment Healthcare Inc (ALHC) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is experiencing negative price momentum, hedge funds are selling, and there are no significant positive trading signals. While analysts are optimistic with raised price targets and the company shows strong revenue growth, the recent public offering and declining net income and EPS are concerning. Holding the stock or waiting for a better entry point is recommended.
The MACD is negatively expanding (-0.194), indicating bearish momentum. RSI is neutral at 32.829, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 18.488), with resistance at 19.686. Overall, the technical indicators suggest a bearish or neutral trend.
The Medicare Advantage market is seen as a growth area, with Alignment positioned well.
The company recently announced a public offering of 13.16 million shares at $19.46, which has diluted shareholder value and caused a negative market reaction. Hedge funds are selling heavily, with a 1606.19% increase in selling activity last quarter. Net income and EPS have declined significantly (-64.60% and -68.75% YoY, respectively).
In Q4 2025, revenue increased by 44.43% YoY to $1.01 billion, but net income dropped by 64.60% YoY to -$11 million. EPS fell by 68.75% YoY to -0.05. Gross margin improved slightly to 11.4%, up 0.44% YoY. The financials show strong revenue growth but declining profitability.
Analysts are optimistic, with multiple firms raising price targets recently. JPMorgan, Baird, KeyBanc, TD Cowen, and Piper Sandler have all increased their targets, with the highest being $30. Ratings are mostly Overweight or Buy, reflecting confidence in the company's long-term potential.
